Vanessa Giannone

1.7k total citations · 1 hit paper
11 papers, 1.2k citations indexed

About

Vanessa Giannone is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Organic Chemistry. According to data from OpenAlex, Vanessa Giannone has authored 11 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Genetics, 4 papers in Pulmonary and Respiratory Medicine and 3 papers in Organic Chemistry. Recurrent topics in Vanessa Giannone's work include Hemoglobinopathies and Related Disorders (4 papers), Lung Cancer Treatments and Mutations (4 papers) and Iron Metabolism and Disorders (3 papers). Vanessa Giannone is often cited by papers focused on Hemoglobinopathies and Related Disorders (4 papers), Lung Cancer Treatments and Mutations (4 papers) and Iron Metabolism and Disorders (3 papers). Vanessa Giannone collaborates with scholars based in United States, France and Italy. Vanessa Giannone's co-authors include Bijoyesh Mookerjee, Bruce E. Johnson, Julien Mazières, Benjamin Besse, Egbert F. Smit, David Planchard, Harry J.M. Groen, Pingkuan Zhang, Anthony M. D’Amelio and Åslaug Helland and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Gastroenterology.

In The Last Decade

Vanessa Giannone

11 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

2017 948 citations David Planchard, Egbert F. Smit et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Vanessa Giannone

Since Specialization

Citations

This map shows the geographic impact of Vanessa Giannone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vanessa Giannone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vanessa Giannone more than expected).

Fields of papers citing papers by Vanessa Giannone

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vanessa Giannone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vanessa Giannone. The network helps show where Vanessa Giannone may publish in the future.

Co-authorship network of co-authors of Vanessa Giannone

This figure shows the co-authorship network connecting the top 25 collaborators of Vanessa Giannone. A scholar is included among the top collaborators of Vanessa Giannone based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vanessa Giannone. Vanessa Giannone is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

#	Work	Indexed citations
1	Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non–Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study 2019 ·Journal of Thoracic Oncology ·Enriqueta Felip, Filippo de Braud, Michela Maur, Herbert H. Loong, Alice T. Shaw, Johan Vansteenkiste, Thomas John, Geoffrey Liu, Martijn P. Lolkema, Giovanni Selvaggi, Vanessa Giannone, Pilar Cazorla, Jason Baum, O. Alejandro Balbin, (unknown), Yvonne Lau, Jeffrey W. Scott, Daniel Shao-Weng Tan	60
2	Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial breakdown → 2017 ·The Lancet Oncology ·David Planchard, Egbert F. Smit, Harry J.M. Groen, Julien Mazières, Benjamin Besse, Åslaug Helland, Vanessa Giannone, Anthony M. D’Amelio, Pingkuan Zhang, Bijoyesh Mookerjee, Bruce E. Johnson	948
3	Phase 2 trial (BRF113928) of dabrafenib (D) plus trametinib (T) in patients (pts) with previously untreated BRAF V600E–mutant metastatic non-small cell lung cancer (NSCLC) 2017 ·Annals of Oncology ·David Planchard, Egbert F. Smit, Harry J.M. Groen, Julien Mazières, Benjamin Besse, Åslaug Helland, Vanessa Giannone, Anthony M. D’Amelio, (unknown), Bijoyesh Mookerjee, Bruce E. Johnson	4
4	Updated survival of patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D + trametinib (T) in the phase II BRF113928 study. 2017 ·Journal of Clinical Oncology ·David Planchard, Benjamin Besse, Tae Min Kim, Élisabeth Quoix, Pierre Jean Souquet, Julien Mazières, Fabrice Barlési, Harry J.M. Groen, Egbert F. Smit, Christina S. Baik, Byoung Chul Cho, Ronan J. Kelly, Mark A. Socinski, Silvia Novello, James R. Rigas, Vanessa Giannone, Anthony M. D’Amelio, Pingkuan Zhang, Bijoyesh Mookerjee, Bruce E. Johnson	34
5	Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: A randomized, multicenter, open‐label, phase I study 2014 ·The Journal of Clinical Pharmacology ·Stephan Petersenn, Jens Bollerslev, Ayman M. Arafat, Jochen Schopohl, Omar Serri, Laurence Katznelson, Janet Lasher, Gareth Hughes, Ke Hu, (unknown), Karina Hermosillo Reséndiz, Vanessa Giannone, Albert Beckers	23
6	Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study 2013 ·Cancer Chemotherapy and Pharmacology ·Edward M. Wolin, Ke Hu, Gareth Hughes, (unknown), Vanessa Giannone, Karina Hermosillo Reséndiz	34
7	Beneficial effects of liraglutide on carotid intima-media thickness in patients with type 2 diabetes: a 8-month prospective study 2013 ·Ultraschall in der Medizin - European Journal of Ultrasound ·(unknown), Manfredi Rizzo, (unknown), (unknown), (unknown), Vanessa Giannone, (unknown), (unknown)	1
8	Long‐term safety and efficacy of deferasirox (Exjade^®) for up to 5 years in transfusional iron‐overloaded patients with sickle cell disease 2011 ·British Journal of Haematology ·Elliott Vichinsky, Françoise Bernaudin, Gian Luca Forni, Renée V. Gardner, (unknown), Matthew M. Heeney, Baba Inusa, Abdullah Kutlar, Peter A. Lane, Liesl Mathias, John B. Porter, Cameron K. Tebbi, Felicia Wilson, Louis Griffel, Wei Deng, Vanessa Giannone, Thomas D. Coates	58
9	Improvement in Liver Pathology of Patients With β-Thalassemia Treated With Deferasirox for at Least 3 Years 2011 ·Gastroenterology ·Yves Deugnier, Bruno Turlin, Martine Ropert, Maria Domenica Cappellini, John B. Porter, Vanessa Giannone, Yiyun Zhang, Louis Griffel, Pierre Brissot	65
10	Long-Term Safety and Efficacy of Deferasirox (Exjade®) In Transfused Patients with Sickle Cell Disease Treated for up to 5 Years 2010 ·Blood ·Elliott Vichinsky, Françoise Bernaudin, Gian Luca Forni, Renée V. Gardner, (unknown), Matthew M. Heeney, Baba Inusa, Abdullah Kutlar, Peter A. Lane, Liesl Mathias, John B. Porter, Cameron K. Tebbi, Felicia Wilson, Louis Griffel, Wei Deng, Vanessa Giannone, Thomas D. Coates	2
11	Deferasirox Improves Liver Pathology In β-Thalassemia Patients with Transfusional Iron Overload 2010 ·Blood ·Yves Deugnier, Bruno Turlin, Victor Dong, Vanessa Giannone, Yiyun Zhang, Louis Griffel, Pierre Brissot	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact